In summary, our study demonstrated that USP22 promotes the growth of hepatocellular carcinoma and resistance to Sorafenib‐induced ferroptosis by removing ubiquitin moieties from non‐histone protein CDK11B and histone H2B. This evidence concerns the gene H2BC12L and hepatocellular carcinoma.